1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Glucokinase

Glucokinase

Hexokinase IV; Hexokinase D

Glucokinase is an enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Glucokinase occurs in cells in theliver, pancreas, gut, and brain of humans and most other vertebrates. In each of these organs it plays an important role in the regulation of carbohydrate metabolism by acting as a glucose sensor, triggering shifts in metabolism or cell function in response to rising or falling levels of glucose, such as occur after a meal or when fasting. Glucokinase has a lower affinity for glucose than the other hexokinases do, and its activity is localized to a few cell types, leaving the other three hexokinases as more important preparers of glucose for glycolysis and glycogen synthesis for most tissues and organs. Mutations of the gene for this enzyme can cause unusual forms of diabetes or hypoglycemia.

Glucokinase Related Products (23):

Cat. No. Product Name Effect Purity
  • HY-N2341
    Palmitelaidic Acid
    Activator ≥99.0%
    Palmitelaidic Acid (9-trans-Hexadecenoic acid) is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.
  • HY-109030
    Dorzagliatin
    Activator 99.68%
    Dorzagliatin (HMS5552), a dual-acting glucokinase (GK) activator, improves glycaemic control and pancreatic β-cell function in type 2 diabetes.
  • HY-10595
    RO-28-1675
    Activator 99.95%
    RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes.
  • HY-19843
    MK-0941
    Activator 99.28%
    MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes.
  • HY-13529
    Globalagliatin
    Activator ≥98.0%
    Globalagliatin (LY2608204) is a activator of glucokinase (GK) with EC50 of 42 nM.
  • HY-147254
    Cadisegliatin
    Activator 99.10%
    Cadisegliatin (TTP-399) is a potential liver-selective glucokinase (GK) activator for type 2 diabetes and has antihyperglycaemic activity.
  • HY-12411
    AMG-3969
    Modulator 99.74%
    AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC50 of 4 nM.
  • HY-15671
    GKA50
    Activator ≥98.0%
    GKA50 is a potent glucokinase activator (EC50=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca2+-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats.
  • HY-100221
    AM-2394
    Activator 99.48%
    AM-2394 is a structurally distinct glucokinase activator (GKA). AM-2394 activates glucokinase (GK) with an EC50 of 60 nM.
  • HY-15675
    AZD1656
    Activator 98.02%
    AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research.
  • HY-108328
    PF-04937319
    Inhibitor 99.78%
    PF-04937319 is a glucokinase activator (GKA) with EC50 value of 154.4  μM, one of the most promising strategies for the treatment of type 2 diabetes mellitus. PF-04937319 is designed to maintain glucose-lowering efficacy while mitigating the risk of hypoglycaemia observed with many other GKAs.
  • HY-133127
    AR453588
    Activator 99.69%
    AR453588 is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 shows anti-hyperglycemic activity.
  • HY-15671A
    GKA50 quarterhydrate
    Activator ≥98.0%
    GKA50 quarterhydrate is a potent glucokinase activator (EC50=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca2+-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats.
  • HY-100181
    PF-04991532
    Activator ≥99.0%
    PF-04991532 is a potent, hepatoselective glucokinase activator with EC50s of 80 and 100 nM in human and rat, respectively.
  • HY-144287
    Glucokinase activator 3
    Activator
    Glucokinase activator 3 is a potent and full Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 has the potential for the research of type 2 diabetes.
  • HY-144289
    BMS-820132
    Activator 99.39%
    BMS-820132 is a partial glucokinase activator with a AC50 of 29 nM.
  • HY-19843A
    MK-0941 free base
    Inhibitor
    MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes.
  • HY-133127A
    AR453588 hydrochloride
    Activator
    AR453588 hydrochloride is a potent and orally bioavailable anti-diabetic glucokinase activator, with an EC50 of 42 nM. AR453588 hydrochloride shows anti-hyperglycemic activity.
  • HY-101788
    Glucokinase activator 1
    Activator
    Glucokinase activator 1 is a liver-directed glucokinase activator with an EC50 of 34 nM.
  • HY-N2341S
    Palmitelaidic acid-d13
    Activator
    Palmitelaidic acid-d13 is the deuterium labeled Palmitelaidic Acid. Palmitelaidic Acid (9-trans-Hexadecenoic acid) is the trans isomer of palmitoleic acid. Palmitoleic acid is one of the most abundant fatty acids in serum and tissue.